📊 AMIX Key Takeaways
Is Autonomix Medical, Inc. (AMIX) a Good Investment?
Autonomix Medical is a pre-revenue company with accelerating losses (-46.5% YoY), burning $12.3M annually in operating cash while holding only $7.0M in cash—providing less than 7 months of runway. Without imminent revenue generation or capital infusion, the company faces existential risk despite a clean balance sheet.
Autonomix Medical remains a pre-revenue medical device company with no demonstrated commercial traction and significant ongoing operating losses. While the balance sheet is currently liquid and leverage is modest, cash burn is high relative to its cash balance, making future capital raises or dilution a meaningful risk unless revenue generation improves materially.
Autonomix Medical, Inc. Key Strengths (AMIX)
- Strong immediate liquidity with $7.0M cash covering 92% of assets and 4.45x current ratio
- Conservative capital structure with only 0.25x debt-to-equity and $5.9M positive equity
- Minimal capital expenditure ($10K) suggests product may be near commercialization phase
- Strong near-term liquidity with cash representing most of total assets
- Low debt burden relative to equity
- Minimal capital expenditure needs keep infrastructure intensity low at this stage
AMIX Stock Risks: Autonomix Medical, Inc. Investment Risks
- Zero revenue with no visible commercialization traction in medical device sector requiring lengthy FDA approval cycles
- Accelerating losses: net income declined 46.5% YoY, indicating burn rate is worsening not improving
- Critical cash runway of less than 7 months at current $12.3M annual operating burn rate, creating imminent dilution or insolvency risk
- Medical device regulatory and market risks combined with unproven commercialization capability
- No insider activity in 90 days suggests limited management confidence in near-term prospects
- No revenue base or gross profit, leaving the business model unproven
- Heavy operating and free cash flow losses imply limited cash runway
- Very weak returns on assets and equity indicate poor current capital efficiency
Key Metrics to Watch
- Quarterly revenue recognition and commercialization timeline
- Monthly operating cash burn rate and cash balance trajectory
- Announcements of capital raises, debt financing, or strategic partnerships
- Product regulatory approval status and customer acquisition metrics
- Quarterly revenue/commercialization progress
- Operating cash burn relative to cash and equivalents
Autonomix Medical, Inc. (AMIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.45x current ratio provides a solid financial cushion.
AMIX Profit Margin, ROE & Profitability Analysis
AMIX vs Healthcare Sector: How Autonomix Medical, Inc. Compares
How Autonomix Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Autonomix Medical, Inc. Stock Overvalued? AMIX Valuation Analysis 2026
Based on fundamental analysis, Autonomix Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Autonomix Medical, Inc. Balance Sheet: AMIX Debt, Cash & Liquidity
AMIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Autonomix Medical, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-6.46 indicates the company is currently unprofitable.
AMIX Revenue Growth, EPS Growth & YoY Performance
AMIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | -$2.7M | $-0.36 |
| Q2 2026 | N/A | -$2.7M | $-1.38 |
| Q1 2026 | N/A | -$2.7M | $-1.07 |
| Q3 2025 | N/A | -$865.0K | $-1.46 |
| Q2 2024 | N/A | -$865.0K | $-2.47 |
| Q1 2024 | N/A | -$865.0K | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Autonomix Medical, Inc. Dividends, Buybacks & Capital Allocation
AMIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Autonomix Medical, Inc. (CIK: 0001617867)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMIX
What is the AI rating for AMIX?
Autonomix Medical, Inc. (AMIX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMIX's key strengths?
Claude: Strong immediate liquidity with $7.0M cash covering 92% of assets and 4.45x current ratio. Conservative capital structure with only 0.25x debt-to-equity and $5.9M positive equity. ChatGPT: Strong near-term liquidity with cash representing most of total assets. Low debt burden relative to equity.
What are the risks of investing in AMIX?
Claude: Zero revenue with no visible commercialization traction in medical device sector requiring lengthy FDA approval cycles. Accelerating losses: net income declined 46.5% YoY, indicating burn rate is worsening not improving. ChatGPT: No revenue base or gross profit, leaving the business model unproven. Heavy operating and free cash flow losses imply limited cash runway.
What is AMIX's revenue and growth?
Autonomix Medical, Inc. reported revenue of $0.0.
Does AMIX pay dividends?
Autonomix Medical, Inc. does not currently pay dividends.
Where can I find AMIX SEC filings?
Official SEC filings for Autonomix Medical, Inc. (CIK: 0001617867) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMIX's EPS?
Autonomix Medical, Inc. has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AMIX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Autonomix Medical, Inc. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AMIX stock overvalued or undervalued?
Valuation metrics for AMIX: ROE of -283.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AMIX's AI grade for 2026?
Our dual AI analysis gives Autonomix Medical, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMIX's free cash flow?
Autonomix Medical, Inc.'s operating cash flow is $-12.3M, with capital expenditures of $10.0K.
How does AMIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -283.5% (avg: 15%), current ratio 4.45 (avg: 2).